[NESTLE] QoQ Cumulative Quarter Result on 31-Dec-2023 [#4]

Stock
[NESTLE] NESTLE (M) BHD
Announcement Date
27-Feb-2024
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
31-Dec-2023 [#4]
Profit Trend
QoQ- 28.94%
YoY- 6.37%
Quarter Report
Latest QR
Upcoming QR
NESTLE's Result
NESTLE's Financial Summary
View:
Show?
Cumulative Result
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Revenue 4,752,028 3,305,845 1,782,581 7,050,879 5,365,592 3,593,331 1,842,409 87.74%
PBT 489,169 385,061 259,095 879,093 702,432 502,158 262,317 51.33%
Tax -114,648 -95,951 -63,582 -219,223 -190,666 -124,094 -65,172 45.57%
NP 374,521 289,110 195,513 659,870 511,766 378,064 197,145 53.20%
-
NP to SH 374,521 289,110 195,513 659,870 511,766 378,064 197,145 53.20%
-
Tax Rate 23.44% 24.92% 24.54% 24.94% 27.14% 24.71% 24.84% -
Total Cost 4,377,507 3,016,735 1,587,068 6,391,009 4,853,826 3,215,267 1,645,264 91.66%
-
Net Worth 572,180 663,634 569,835 675,360 694,120 719,914 537,004 4.30%
Dividend
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Div 246,225 164,150 - 628,460 328,300 164,150 - -
Div Payout % 65.74% 56.78% - 95.24% 64.15% 43.42% - -
Equity
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Net Worth 572,180 663,634 569,835 675,360 694,120 719,914 537,004 4.30%
NOSH 234,500 234,500 234,500 234,500 234,500 234,500 234,500 0.00%
Ratio Analysis
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
NP Margin 7.88% 8.75% 10.97% 9.36% 9.54% 10.52% 10.70% -
ROE 65.46% 43.56% 34.31% 97.71% 73.73% 52.52% 36.71% -
Per Share
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
RPS 2,026.45 1,409.74 760.16 3,006.77 2,288.10 1,532.34 785.68 87.74%
EPS 159.71 123.29 83.37 281.39 218.24 161.22 84.07 53.20%
DPS 105.00 70.00 0.00 268.00 140.00 70.00 0.00 -
NAPS 2.44 2.83 2.43 2.88 2.96 3.07 2.29 4.30%
Adjusted Per Share Value based on latest NOSH - 234,500
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
RPS 2,026.45 1,409.74 760.16 3,006.77 2,288.10 1,532.34 785.68 87.74%
EPS 159.71 123.29 83.37 281.39 218.24 161.22 84.07 53.20%
DPS 105.00 70.00 0.00 268.00 140.00 70.00 0.00 -
NAPS 2.44 2.83 2.43 2.88 2.96 3.07 2.29 4.30%
Price Multiplier on Financial Quarter End Date
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Date 30/09/24 28/06/24 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 -
Price 104.00 121.50 118.20 117.60 126.50 131.00 137.10 -
P/RPS 5.13 8.62 15.55 3.91 5.53 8.55 17.45 -55.68%
P/EPS 65.12 98.55 141.77 41.79 57.96 81.25 163.08 -45.68%
EY 1.54 1.01 0.71 2.39 1.73 1.23 0.61 85.09%
DY 1.01 0.58 0.00 2.28 1.11 0.53 0.00 -
P/NAPS 42.62 42.93 48.64 40.83 42.74 42.67 59.87 -20.22%
Price Multiplier on Announcement Date
30/09/24 30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 CAGR
Date 24/10/24 25/07/24 29/04/24 27/02/24 26/10/23 27/07/23 25/04/23 -
Price 102.50 122.00 126.90 121.50 124.90 132.00 136.50 -
P/RPS 5.06 8.65 16.69 4.04 5.46 8.61 17.37 -55.95%
P/EPS 64.18 98.96 152.20 43.18 57.23 81.88 162.36 -46.04%
EY 1.56 1.01 0.66 2.32 1.75 1.22 0.62 84.68%
DY 1.02 0.57 0.00 2.21 1.12 0.53 0.00 -
P/NAPS 42.01 43.11 52.22 42.19 42.20 43.00 59.61 -20.75%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment